Despite a notable decrease in quarterly revenue and increased net loss, OmniAb showed strong momentum in partnerships and active programs, with high potential future milestones and successful technology launches, suggesting a positive outlook.

Company Guidance

During the OmniAb Inc. Second Quarter 2025 Financial Results and Business Update Conference Call, the company provided several key metrics and guidance for the remainder of the year. OmniAb reported Q2 revenue of $3.9 million, a decrease from $7.6 million the previous year, primarily due to lower milestone achievements and service revenue. The company's operating expenses decreased to $20.1 million from $23.9 million, with reductions in R&D and G&A expenses. OmniAb maintained its 2025 revenue guidance of $20 million to $25 million and operating expenses between $85 million and $90 million, noting that approximately 40% of these expenses are noncash. The company highlighted its xPloration Partner Access Program, which has begun generating revenue and is expected to diversify its income streams. OmniAb ended Q2 with 100 active partners and 381 active programs, with a year-to-date net increase of 18 programs. The company also reduced its headcount from 114 to 87 employees, anticipating $7 million in annual cash savings. OmniAb's outlook remains on track, with plans to launch new technologies later in the year.

Strong Deal Flow and Partnerships

OmniAb added a number of new partners in the first half of 2025, setting a pace for one of their strongest years yet, with the xPloration Partner Access Program receiving a strong market response.

Growth in Active Programs

The number of active programs increased to 381 as of the quarter-end, with a year-to-date net increase of 18 programs, more than doubling the net additions through the first half of 2024.

Significant Milestone Payments Potential

OmniAb's antibody programs have over $3 billion in total remaining contracted potential milestone payments, with an increased average royalty rate of 3.36% from 3.2%.

Advancements in Clinical Programs

A third OmniChicken-derived antibody entered human clinical trials in Q2, with post-discovery stage programs experiencing 22% growth from the prior year period.

xPloration Launch Success

The xPloration system was sold and installed soon after launch, creating a new revenue stream from sales and consumables, with high throughput and positive market feedback.

OmniAb (OABI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OABI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	-0.14 / -	-0.16	―	―	―
Aug 06, 2025	2025 (Q2)	-0.15 / -0.15	-0.13	-15.38% (-0.02)
May 08, 2025	2025 (Q1)	-0.16 / -0.17	-0.19	10.53% (+0.02)
Mar 18, 2025	2024 (Q4)	-0.11 / -0.12	-0.14	14.29% (+0.02)
Nov 12, 2024	2024 (Q3)	-0.14 / -0.16	-0.16	0.00% (0.00)
Aug 08, 2024	2024 (Q2)	-0.17 / -0.13	-0.15	13.33% (+0.02)
May 09, 2024	2024 (Q1)	-0.16 / -0.19	-0.06	-216.67% (-0.13)
Mar 20, 2024	2023 (Q4)	-0.14 / -0.14	0.07	-300.00% (-0.21)
Nov 09, 2023	2023 (Q3)	-0.14 / -0.16	-0.285	43.86% (+0.12)
Aug 10, 2023	2023 (Q2)	-0.12 / -0.15	-0.03	-400.00% (-0.12)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

OABI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$1.93	$1.88	-2.59%
May 08, 2025	$1.57	$1.44	-8.28%
Mar 18, 2025	$3.19	$2.54	-20.38%
Nov 12, 2024	$4.49	$4.07	-9.35%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Omniab, Inc. (OABI) report earnings?

Omniab, Inc. (OABI) is schdueled to report earning on Nov 18, 2025, TBA (Confirmed).

What is Omniab, Inc. (OABI) earnings time?

Omniab, Inc. (OABI) earnings time is at Nov 18, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is OABI EPS forecast?

OABI EPS forecast for the fiscal quarter 2025 (Q3) is -0.14.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing